THER-02. EVALUATION OF THE ONCOLYTIC VIRUS DELTA24-RGD AS AN ANTI-TUMOR AGENT IN PRECLINICAL MODELS OF LOCALIZED AND DISSEMINATED AT/RT

Current therapies for atypical teratoid/rhabdoid tumors (AT/RTs) are suboptimal, resulting in a 2-year OS below 20% and the development of severe side effects. Therefore, we need to explore alternative therapeutic approaches for this disease. Since the virus Delta24-RGD has already demonstrated its...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Moure, Marc, González-Huarriz, Marisol, de la Nava, Daniel, Marrodán, Lucía, Gomez-Manzano, Cande, Fueyo, Juan, Patiño-García, Ana, Alonso, Marta M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Viral/Gene Therapy and other Novel Therapies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715559/
http://dx.doi.org/10.1093/neuonc/noaa222.852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715559/
http://dx.doi.org/10.1093/neuonc/noaa222.852

Ejemplares similares